Objective: To describe the development of a web-based data collection tool to track the management and outcomes of uveal melanoma patients.
Design: Description of a clinical registry.
Participants: Patients with uveal melanoma.
Objective: Ruthenium-106 brachytherapy is commonly used to treat uveal melanomas. Most centres prescribe a radiation dose to the tumour apex that is calculated with the tumour located in the centre of the plaque. Recent work suggests that D-the minimum radiation dose delivered to 99% of tumour volume-may be a better predictor of tumour control than apex dose.
View Article and Find Full Text PDF